[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

615.P1.47 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 4, 2010: 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML

Geoffrey L. Uy, MD1, Camille N. Abboud, MD1, Amanda F. Cashen, MD2, John F. DiPersio, MD, PhD2, Keith E. Stockerl-Goldstein, MD2, Ravi Vij, MBBS, MD2 and Peter Westervelt, MD, PhD2

1Division of Oncology, Washington University School of Medicine, St. Louis, MO
2Division of Oncology, Washington University School of Medicine, Saint Louis, MO

Poster Board Number: I-40
Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Kiran Naqvi, MD1*, Farhad Ravandi, MD1, Hagop Kantarjian, MD1, Gautam Borthakur, MD1, Alessandra Ferrajoli, MD1, Deborah A Thomas, MD1, Charles Asa Koller2, Marina Konopleva, MD, PhD1, Anna Byrd, RN1*, Monica Kwari, BSN1 and Stefan Faderl, MD1

1Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: I-41
Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD1*, Shugo Kowata, MD1*, Kazunori Murai, MD, PhD1*, Shigeki Ito, MD, PhD1, Tomoaki Akagi, MD, PhD2*, Koumei Kubo, MD, PhD2*, Kenichi Sawada, MD, PhD3 and Yoji Ishida, MD, PhD1

1Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
2Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan
3Hematology, Nephrology and Rheumatology, Akita Univ. Graduate School of Med., Akita, Japan

Poster Board Number: I-42
Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection

George Ansstas, MD1*, Waseem Touma, MD2*, Camille Adeimy, MD3*, Gao Feng4*, Peter Westervelt, MD, PhD5*, Camille N. Abboud, MD6, Geoffrey L. Uy, MD7*, Keith E. Stockerl-Goldstein, MD7, Amanda Cashen, MD6, John F. DiPersio, MD, PhD8 and Ravi Vij, MBBS, MD7

1Hematology and Oncology, Washington University, Saint Louis, MO
2Saint Louis University, Saint Louis
3Saint Louis University, Saint Louis, MO
4Biostatistics, Washington University, Saint Louis, MO
5Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
6Washington University School of Medicine, Saint Louis, MO
7Division of Oncology, Washington University School of Medicine, Saint Louis, MO
8Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO

Poster Board Number: I-43
Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 580 Patients with Acute Leukemia In China and Japan

Guoqing Wei, MD, PhD1* and Delong Liu, MD, PhD2

1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2Division of Hematology /Oncology, New York Medical College, Valhalla, NY

Poster Board Number: I-44
Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens

Pamela S. Becker, MD, PhD1, Hagop M. Kantarjian2, Frederick R. Appelbaum, MD3, Stephen H. Petersdorf, MD4*, Barry Storer, PhD5*, Sherry A. Pierce, RN, BS6*, Jianqin Shan, PhD7*, Paul C. Hendrie, MD, PhD1, John M. Pagel, MD, PhD8, Andrei Shustov, MD1*, Derek L. Stirewalt, MD3, Stefan Faderl, MD9, Elizabeth Harrington, RN8* and Elihu H. Estey, MD3

1University of Washington, Seattle, WA
2Leukemia, MD Anderson Cancer Center, Houston, TX
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
5Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
6Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
8Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: I-45
Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy

Jorge Sierra, MD1, Montserrat Hoyos1*, Josep F. Nomdedeu, MD2*, Jordi Esteve, MD, PhD3, Rafael F. Duarte, MD, PhD4, Josep-Maria Ribera, MD, PhD5, Mar Tormo, MD, PhD6, Ramon Guardia7*, Andreu Llorente8*, Javier Bueno9*, Juan Besalduch10, M. Paz Queipo11*, Josep M. Marti-Tutusaus12*, Carmen Pedro1*, Pio Torres13*, Antoni Garcia14*, Inmaculada Heras15*, Joan Bargay16*, Llorenç Font17*, Jose Gonzalez, MD18*, Antonia Sampol, MD, PhD19*, Olga Salamero, MD20*, Lourdes Escoda8*, David Gallardo, MD, PhD21*, Marisa Calabuig6*, Albert Oriol5*, Montserrat Arnan1*, Marta Pratcorona1* and Salut Brunet22*

1On behalf of CETLAM Cooperative Group, Barcelona, Spain
2Department of Hematology, On behalf of CETLAM Cooperative Group, Barcelona, Spain
3Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
4Clinical Hematology, Hospital Duran i Reynals , Barcelona, Spain
5On behalf of CETLAM Cooperative Group, Badalona, Spain
6On behalf of CETLAM Cooperative Group, Valencia, Spain
7On behalf of CETLAM Cooperative Group, Girona, Spain
8On behalf of CETLAM Cooperative Group, Tarragona, Spain
9Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
10On behalf of CETLAM Cooperative Group, Spain
11On behalf of CETLAM Cooperative Group, Málaga, Spain
12On behalf of CETLAM Cooperative Group, Terrassa, Spain
13On behalf of CETLAM Cooperative Group, A Coruña, Spain
14On behalf of CETLAM Cooperative Group, Lleida
15On behalf of CETLAM Cooperative Group, Murcia, Spain
16Hospital Sont Llatzer, Palma de Mallorca, Spain
17On behalf of CETLAM Cooperative Group, Tortosa, Spain
18On behalf of CETLAM Cooperative Group, Sevilla, Spain
19On behalf of CETLAM Cooperative Group, Palma de Mallorca, Spain
20Hematology, Hospital Vall d´Hebron, Barcelona, Spain
21Hematology, Hospital de Josep Trueta, Girona, Gerona, Spain
22Hematology, Hospital de Sant Pau, Barcelona, Spain

Poster Board Number: I-46
Treatment of Elderly Patients with Acute Myeloid Leukemia Adjusted to Age, Performance Status, Organ Function and the Presence of Co-Morbidities. Final Results of the Polish Adult Leukemia Group (PALG) 1/2005 Study

Bozena Katarzyna Budziszewska1*, Agnieszka Pluta, MD, PhD2*, Kazimierz Sulek3*, Tadeusz Robak4, Sebastian Giebel, MD5*, Aleksandra Holowiecka6*, Waldemar Sawicki3*, Anna Ejduk, MD, PhD7*, Elzbieta Patkowska1*, Joanna Manko8*, Justyna Gajkowska-Kulik9*, Jaroslaw Piszcz10, Monika Mordak-Domagala11*, Jerzy Holowiecki, MD, PhD5, Slawomira Kyrcz-Krzemien12, Krzysztof Warzocha, MD13*, Maria Domagala14*, Anna Dmoszynska8, Malgorzata Calbecka9*, Janusz Kloczko10*, Kazimierz Kuliczkowski, Professor15*, Wieslaw Wiktor Jedrzejczak16*, Andrzej Lange11, Malgorzata Razny17* and Agnieszka Wierzbowska4*

1Dept of Haematology, Institute of Haematology and Blood Transfusion, Warszawa, Poland
2Department of Hematology, Medical University, Lodz, Poland
3Dept of Haematology, Military Medical Institute, Warszawa, Poland
4Dept of Haematology, Medical University of Lodz, Lodz, Poland
5Dept of Bone Marrow Transplantation, Cancer Center and Institute of Oncology, M.Sklodowska-Curie Memorial, Gliwice, Poland
6Dept of Bone Marrow Transplantation, Comprehensive Cancer Center, M.Sklodowska-Curie Memorial Institute, Gliwice, Poland
7Department of Hematology, Institute of Hematology and Blood Transfusion, Warsow, Poland
8Dept of Haematology, University School of Med., Lublin, Poland
9Dept of Haematology, Nicolaus Copernicus Hospital, Torun, Poland
10Hematology Department, Medical University in Bialystok, Bialystok, Poland
11Lower Silesian Ctr. for Cellular Transpl w/NPBMOR, Wroclaw, Poland
12Department of Hematology and Bone Marrow Transplantation, Silesian Medical University in Katowice, Katowice, Poland
13Department of Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland
14Dept of Haematology, Center of Oncology-Kielce, Kielce, Poland
15Haematology , Wroclaw Medical University, Wroclaw, Poland
16Medical University Warsaw, Warsaw, Poland
17Dept of Haematology, Rydygier Memorial Hospital, Krakow

Poster Board Number: I-47
Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML

Sheena Sahota, M.D.*, Melissa L Larson, MD, Margaret C Keller, ACNP*, Jamile M. Shammo, MD, Allison Zindell*, Bharathi Muthusamy*, Stephanie A. Gregory, MD* and Parameswaran Venugopal, MD

Sections of Hematology & Stem Cell Transplantation, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL

Poster Board Number: I-48
Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone

Melissa L Larson, MD1, Sheena Sahota, M.D.1*, Margaret C Keller, ACNP1*, Bharathi Muthusamy1*, Allison Zindell1*, Jamile M. Shammo, MD2, Stephanie A. Gregory, MD2* and Parameswaran Venugopal, MD1

1Sections of Hematology & Stem Cell Transplantation, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL
2Sections of Hematology and Stem Cell Transplantation, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL

Poster Board Number: I-49
Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML

Christine L Phillips, MD1, Stella M. Davies, MBBS, PhD2, Richard McMasters, MD3, Maureen O'Brien, MD, MS1, Michael J. Absalon, MD, PhD1, Jeffrey A. Moscow, MD4, Teresa Smolarek, PhD5* and John P. Perentesis, MD1*

1Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Department of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
4Pediatric Hem./Onc., University of Kentucky, Lexington, KY
5Division of Human Genetics, Cincinnati Children's Hospital Med. Ctr., Cincinnati, OH

Poster Board Number: I-50
Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children’s Oncology Group

Lillian Sung, MD, PhD1, Richard Aplenc, MD, MSCE2*, Todd A. Alonzo, PhD3, Robert B. Gerbing, MS4*, Soheil Meshinchi, MD, PhD5, Laura Burden, CCRP4*, Susana C. Raimondi, PhD6, Betsy A. Hirsch, PhD7*, Samir Kahwash, MD8*, Amy Heerema-McKenney, MD9*, Laura Winter, PharmD10*, Kathleen Glick, BA, CCRP11*, Patti Byron, MSN, RN12*, Tanya Wallas, MS4*, Franklin O. Smith, MD13 and Alan S. Gamis, MD, MPH14

1Dept. of Pediatrics, Div. of Hem./Onc., The Hospital for Sick Children, Toronto, ON, Canada
2The Children's Hospital of Philadelphia, Philadelphia, PA
3Keck School of Medicine, University of Southern California, Los Angeles, CA
4Children's Oncology Group, Arcadia, CA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
7Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN
8Nationwide Children's Hospital, Columbus, OH
9Pathology, Stanford University Medical Center, Stanford, CA
10Seattle Childrens Hospital, Seattle, WA
11Maine Children's Cancer Program, Scarborough, ME
12Oncology/Hematology/BMT, British Colombia Children's Hospital, Vancouver, BC, Canada
13Div. of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
14Division of Hematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO

Poster Board Number: I-51
High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children’s Oncology GroupClinically Relevant Abstract

Lillian Sung, MD, PhD1, Todd A. Alonzo, PhD2, Robert B. Gerbing, MS3*, Richard Aplenc, MD, MSCE4*, Soheil Meshinchi, MD, PhD5, Laura Burden, CCRP3*, Susana C. Raimondi, PhD6, Betsy A. Hirsch, PhD7*, Samir Kahwash, MD8*, Amy Heerema-McKenney, MD9*, Laura Winter, PharmD10*, Kathleen Glick, BA, CCRP11*, Patti Byron, MSN, RN12*, Tanya Wallas, MS3*, Franklin O. Smith, MD13 and Alan S. Gamis, MD, MPH14

1Dept. of Pediatrics, Div. of Hem./Onc., The Hospital for Sick Children, Toronto, ON, Canada
2Keck School of Medicine, University of Southern California, Los Angeles, CA
3Children's Oncology Group, Arcadia, CA
4Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
7Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN
8Nationwide Children's Hospital, Columbus, OH
9Pathology, Stanford University Medical Center, Stanford, CA
10Seattle Childrens Hospital, Seattle, WA
11Maine Children's Cancer Program, Scarborough, ME
12Oncology/Hematology/BMT, British Colombia Children's Hospital, Vancouver, BC, Canada
13Div. of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
14Division of Hematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO

Poster Board Number: I-52
Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia

Hiroto Inaba, MD, PhD1, Jeffrey E Rubnitz, MD, PhD1, Elaine Coustan-Smith, MS1*, Lie Li2*, Brian D Furmanski, PhD2*, Gerard P Mascara2*, Sheila A Shurtleff, PhD3*, Stanley B Pounds, PhD4*, Ching-Hon Pui, MD1, Raul C Ribeiro, MD1, Dario Campana, MD, PhD1 and Sharyn D Baker, PharmD, PhD2*

1Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
3Pathology, St. Jude Children's Research Hospital, Memphis, TN
4Biostatistics, St. Jude Children's Research Hospital, Memphis, TN

Poster Board Number: I-53
Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL)

Hideki Muramatsu, MD, PhD1*, Yasuhide Hayashi, MD, PhD2, Machiko Kawamura, MD, PhD3, Seiji Kojima, MD, PhD1*, Miharu Yabe4*, Keiichi Isoyama5*, Tomohiko Taki, MD, PhD6, Kohichiro Tsuji, MD, PhD7, Masahiro Tsuchida8, Atsushi Manabe9*, Etsuro Ito, MD, PhD10, Shotaro Iwamoto, MD, PhD11*, Hiromi Kato12*, Aiko Sumie13*, Takashi Taga, MD, PhD14*, Keiko Nomura15*, Daisuke Hasegawa, MD, PhD16*, Ken-ichiro Watanabe, MD, PhD17* and Akira Kikuchi18*

1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Dept. of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan
3Div. of Peds., Tokyo Metro. Cancer and Infectious Diseases Center Komagome Hosp., Tokyo, Japan
4Department of Pediatrics, Tokai University School of Medicine
5Department of Pediatrics, Showa University Fujigaoka Hospital, Tokyo
6Department of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan
7Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
8Pediatric Hematology/Oncology, Ibaraki Children's Hospital, Mito, Japan
9Pediatrics, Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
10School of Medicine Dept. of Pediatrics, Hirosaki University, Hirosaki, Japan
11Graduate School of Medicine Dept. of Pediatrics, Mie University, Tsu, Japan
12Department of Pediatrics, Yokohama Ciity University
13Department of Pediatrics, Graduate School of Medical Science, Kyusyu University
14Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan
15Department of Pediatrics, Graduate School of Medicine, University of Toyama
16Department of Pediatrics, St Luke's International Hospital, Tokyo, Japan
17Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, Japan
18Department of Pediatrics, Teikyo University School of Medicine

Poster Board Number: I-54
Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia

Dirk Reinhardt, MD, PhD1, Christian M. Zwaan, MD, PhD2, Annette Sander3*, Christine Neuhoff3*, Gertjan J. Kaspers, MD, PhD4 and Ursula Creutzig, MD5

1Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
2Erasmus MC-Sophia Children's Hosp. Dept. of Pediatric Hem./Onc., Erasmus MC-Sophia Children's Hosp., Rotterdam, Netherlands
3Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
4Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands
5Hematology/Oncology, University Children's Hospital Muenster, Muenster, Germany

Poster Board Number: I-55
Good General Health In Survivors of Childhood AML Treated with Chemotherapy Only: A NOPHO-AML StudyClinically Relevant Abstract

Henrik Hasle, M.D.1, Heidi Glosli2*, Kirsi Jahnukainen3*, Marianne Jarfelt4*, Guðmundur Jónmundsson5*, Johan Malmros-Svennilson6*, Karsten Nysom7* and Lene Molgaard-Hansen1*

1Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
2Pediatrics, University Hospital Oslo, Oslo, Norway
3Pediatrics, University Central of Helsinki, Helsinki, Finland
4Pediatric Oncology, The Queen Silvia Children's Hospital, Gothenburg, Sweden
5Pediatrics, Landspitalinn University Hospital, Reykjavik, Iceland
6Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden
7Pediatric Clinic II, University Hospital Rigshospital, Copenhagen, Denmark

Poster Board Number: I-56
Clinical Features and Outcomes of Elderly Patients with Acute Promyelocytic Leukemia (APL) - the Japan Adult Leukemia Study Group APL97 Study -Clinically Relevant Abstract

Takaaki Ono, MD, PhD1*, Akihiro Takeshita, MD, PhD2, Yuji Kishimoto, MD, PhD3*, Hitoshi Kiyoi, MD, PhD4, Masaya Okada, MD, PhD5*, Yasukazu Kawai, MD, PhD6*, Motohiro Tsuzuki, MD, PhD7*, Kentaro Horikawa, MD, PhD8, Mitsuhiro Matsuda, MD, PhD9, Katsuji Shinagawa, MD, PhD10, Fumihiko Monma, MD, PhD11*, Shigeki Ohtake, MD, PhD12, Chiaki Nakaseko, MD, PhD13, Masatomo Takahashi, MD14, Fumiharu Yagasaki, MD, PhD15*, Yukihiko Kimura, MD, PhD16*, Masako Iwanaga, MD, PhD, MPH17, Norio Asou, MD, PhD18, Tomoki Naoe, MD, PhD19* and Ryuzo Ohno, MD20

1Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
2Department of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
3First Department of Internal Medicine, Kansai Medical University, Moriguchi, Japan
4School of Medicine Infectious Diseases, Nagoya University, Nagoya, Japan
5Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Japan
6First Department of Internal Medicine, Fukui prefectural Hospital, Japan
7Department of Hematology, Fujita Health University, Toyoake, Aichi, Japan
8School of Med. Hematology, Kumamoto University, Kumamoto, Japan
9Dept. of Internal Med., PL General Hospital, Tondabayashi, Japan
10Graduate School, Okayama University, Okayama, Japan
11Department of Hematology, Mie University Graduate School of Medicine, Japan
12School of Health Sciences, Kanazawa University, Kanazawa, Japan
13Department of Hematology, Chiba University Graduate School of Medicine, Chiba, Japan
14School of Med. Hem./Onc. & Internal Med., St. Marianna Univ., Kawasaki, Japan
15Internal Medicine, Saitama Medical University, Kawagoe, Japan
16First Department of Internal Medicine, Tokyo Medical University, Japan
17Department of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
18Hematology, Kumamoto University, Kumamoto, Japan
19Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan
20Aichi Cancer Center, Nagoya, Japan

Poster Board Number: I-57
High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL)

Ramzi Jeddi1*, Béchir Achour2*, Agnès Guerci-Bresler, MD, PhD3*, Héla Ghédira4*, Hervé Dombret3*, Françoise Huguet3*, Patrice Chevallier3*, Norbert Vey3*, Stephane de Botton3*, Dominique Bordessoule3*, Beatrice U. Muller3*, Virginie Eclache3*, Claude Gardin5*, Balkis Meddeb4*, Lionel Adès3* and Pierre Fenaux, MD, PhD6

1Hematology, Aziza Othmana University Hospital, Tunis, Tunisia
2Hematology, Avicenne Hospital, Paris, France
3French-Belgian-Swiss APL group
4Aziza Othmana University Hospital, Tunis, Tunisia
5Hopital Avicenne - Service d'hématologie clinique, Bobigny, France
6Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France

Poster Board Number: I-58
Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Anti-Leukemia Effects of All-Trans Retinoic Acid In Acute Promyelocytic Leukemia Cells

Takayuki Ikezoe1, Jing Yang1*, Chie Nishioka1*, Mayuka Isaka1*, Naomi Iwabu1*, Mizu Sakai1*, Ayuko Taniguchi1*, Kazuto Togitani1*, Goichi Honda2* and Akihito Yokoyama1*

1Hematology and Respiratory Medicine, Kochi University, Nankoku, Japan
2Asahi Kasei Pharma

Poster Board Number: I-59
Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL)

Farhad Ravandi, MD1, Elihu H. Estey, MD2, Jorge E. Cortes3, Susan O'Brien, MD4, Sherry A. Pierce, RN, BS5*, Mark Brandt, BS5*, Alessandra Ferrajoli, MD6, Gautam Borthakur7, Marina Konopleva, MD, PhD8*, Srdan Verstovsek, MD, PhD9, Guillermo Garcia-Manero, MD10, Stefan Faderl, MD11 and Hagop M. Kantarjian7

1Leukemia, M.D. Anderson Cancer Center, Houston, TX
2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
3The University of Texas MD Anderson Cancer Center, Houston, TX
4M. D. Anderson Cancer Center
5Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
6Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Leukemia, MD Anderson Cancer Center, Houston, TX
8Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
10MD Anderson Cancer Center, Houston, TX
11Department of Leukemia, Unit 428, The University of Texas, M. D. Anderson Cancer Center, Houston, TX

Poster Board Number: I-60
Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital

Shu-Lan Wu, MD1*, Dao-Pei Lu, MD1, Yan-Li Zhao, MD2*, Lan-Qing Liang, MD1*, Jun-Bao He, MD1*, Wei Zou, MD1*, Xin-Hong Fei, MD1*, Bin Jiang3*, Fu-Xiang Shan, MD1*, Ping-Di Yang, MD1*, Jie Zhao, MD1* and Chun-Rong Tong, MD1*

1Hematology, Beijing Daopei Hospital, Beijing, China
2Bone Marrow Transplantation, Beijing Daopei Hospital, Beijing, China
3Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Poster Board Number: I-61
Risk Factors and Clinical Outcome of Central Nervous System (CNS) Leukemia In Patients with Acute Promyelocytic Leukemia (APL) on Long-Term Oral Arsenic Trioxide Maintenance

Wing Y Au1*, Cyrus Kumana, MD1* and Yok lam Kwong, MD2*

1Department of Medicine, Queen Mary Hospital, Hong Kong, China
2Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong

Poster Board Number: I-62
Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010Clinically Relevant Abstract

Jean-Baptiste Micol1*, Emmanuel Raffoux, MD, PhD2*, Nicolas Boissel3, Etienne Lengliné, MD4*, Emmanuel Canet5*, Thierry Leblanc, MD6*, Marie-Thérèse Daniel7*, Adrienne de Labarthe8*, Odile Maarek9*, Bruno Cassinat10*, Christine Chomienne, MD, PhD11*, Lionel Adès12*, André Baruchel13*, Laurent Degos14*, Elie Azoulay, MD, PhD15* and Hervé Dombret16*

1Department of Hematology, Hôpital Saint-Louis, AP-HP, Université Paris 7, Paris, France
2Hôpital Saint-Louis APHP University Paris VII, Paris, France
3Service d' Hematologie, Hopital Saint-Louis, Paris, France
4Hematology department, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France
5Medical ICU, Saint-Louis Hospital, Paris, France
6Service d'onco-Hematologie pédiatrique, Hopital Robert Debré, Paris, France
7Hematology Laboratory, Paris, France
8Hematology Laboratory and Inserm U944, Hopital Saint-Louis, Paris, France
9Cytogenetic department, Saint-Louis Hospital, Paris, France
10Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
11Institut Universitaire d'Hématologie, INSERM UMR-S 940, Paris, France
12French-Belgian-Swiss APL group
13Dept. of Pediatric Hematology, Hopital Robert Debré, Paris, France
14Hôpital Saint Louis, Paris, France
15Medical ICU, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France
16Hôpital Saint-Louis, Paris, France

Poster Board Number: I-63
Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials

Gonzalo Ariel Ferini, PhD, MD1*, Emmanuel Raffoux, MD, PhD2*, Agnès Guerci3*, Arnaud Pigneux, MD, PhD4*, Françoise Huguet, MD5*, Norbert Vey6*, Thierry Lamy, MD, PhD7, Beatrice Muller8*, Patrice Chevallier9*, Sylvie Castaigne10, Pascal Turlure11*, Augustin Ferrant12*, Norbert Ifrah13, Stephane de Botton14*, Hervé Dombret15*, Lionel Ades1* and Pierre Fenaux, MD, PhD16

1Hopital Avicenne, Bobigny, France
2Hôpital Saint-Louis APHP University Paris VII, Paris, France
3CHU Nancy, Nancy, France
4Hopital du Haut-Lévèque, Pessac, France
5Hôpital Purpan, Université Toulouse, Toulouse, France
6Institut Paoli Calmettes, Marseille
7Hematology Dept, CHU, Rennes, France
8University Hospital Berne, Bern, Switzerland
9CHU Nantes, Université Nantes, Nantes, France
10Hematology, Hopital de Versailles, UVSQ, Le Chesnay, France
11CHU, Limoges, France
12French-Belgian-Swiss APL group, Bobigny, Belgium
13Service des Maladies du Sang, CHU Angers, France
14Institut Gustave Roussy, Villejuif, France
15Hôpital Saint-Louis, Paris, France
16Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France

Poster Board Number: I-64
Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO)

Alireza Eghtedar, MD1*, Stefan Faderl, MD2*, Hagop M Kantarjian3*, Susan O'Brien, MD4, Guillermo Garcia-Manero, MD5, Alessandra Ferrajoli, MD6, Tapan Kadia, MD5, Sherry A. Pierce, RN, BS7*, Jenny Shan, PhD8*, Jorge E. Cortes9 and Farhad Ravandi, MD5

1Leukemia, University of Texas, Houston, TX
2Leukemia, university of texas/MDAnderson, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Leukemia, MD Anderson Cancer Center, Houston, TX
6Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
8Leukemia Department, MD Anderson Cancer Center, Houston, TX
9The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: I-65

*signifies non-member of ASH